#USA #Ajinomoto #Peptide Manufacturing #Olon #Tokyo and Milan

Strategic Collaboration between Ajinomoto Bio-Pharma and Olon S.p.A.

On October 28, 2025, Ajinomoto Bio-Pharma Services announced a pivotal partnership with Olon S.p.A., aimed at revolutionizing large-scale peptide and protein manufacturing. The collaboration is set to leverage each company's strengths to provide enhanced services for pharmaceutical and biotechnology clients, specifically focusing on high-demand products such as GLP-1 analogs that play a significant role in treating obesity and Type II diabetes.

The Objectives of the Partnership

Ajinomoto Bio-Pharma, a recognized leader in biopharmaceutical contract development and manufacturing, combines its advanced microbial CORYNEX® peptide and protein manufacturing platform with Olon’s extensive microbial fermentation capabilities. These capabilities include fermenters with over 100,000 liters of capacity, known for their data quality and efficiency.

Accelerating Innovation in Drug Manufacturing

The urgency for efficient drug manufacturing processes has never been greater, with increasing global demand for effective treatments in the healthcare sector. Yasuyuki Otake, Corporate Executive and General Manager of Ajinomoto’s Bio-Pharma Services Department, emphasized that this partnership is committed to accelerating the development and supply of advanced peptides and proteins.

In joint statements, both Yasuyuki Otake and Andrea Conforto, Vice President of CDMO Biotech at Olon S.p.A., highlighted the potential of this collaboration to enhance customer satisfaction and improve patient outcomes sustainably. They underscored the importance of melding quality and sustainability, paving the way for cutting-edge therapeutic solutions that prioritize environmental responsibility.

Focus on Sustainability

Sustainability stands at the forefront of their partnership. By integrating environmentally friendly production methods with high-efficiency fermentation processes, Ajinomoto and Olon aim to reduce the overall environmental footprint of biologics manufacturing. This progressive approach not only benefits the pharmaceutical clients but also contributes positively to broader societal goals.

CORYNEX® Technology Benefits

One of the game-changing aspects of CORYNEX® technology is its ability to streamline the manufacturing process significantly. It allows for the direct secretion of soluble and biologically active proteins into the media during production, ensuring high titers and purity without needing an expression inducer. This innovation is pivotal for producing reliable and effective peptides swiftly and efficiently.

Olon’s Role in the Partnership

Olon brings a wealth of expertise in microbial fermentation, having established itself as one of Europe’s largest third-party producers in this field. With its impressive infrastructure and experience in handling both high-potent and toxic compounds, Olon is well-positioned to manage the complexities of large-scale production effectively. This collaboration promises to create a seamless path from development to commercial manufacturing for clients in biotechnology.

Conclusion

The partnership between Ajinomoto Bio-Pharma Services and Olon S.p.A. marks a significant advancement in the field of peptide and protein manufacturing. By prioritizing both quality and sustainability, they strive to set new industry standards that will lead to improved health outcomes for patients worldwide. As they move forward, the collaboration is expected to foster innovation, efficiency, and environmental stewardship across the biopharmaceutical landscape.

For more information on Ajinomoto Bio-Pharma Services, visit www.AjiBio-Pharma.com. Interested parties can explore Olon’s initiatives at www.olonspa.com.